Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs S&P500 ETF (SPY) Price & Performance

Ginkgo Bioworks Holdings IncTrade
S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs S&P500 ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.12 (market cap $590.53M), while S&P500 ETF trades at $753.19. The key difference: S&P500 ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.

DNASPY
Market Cap
$590.53M
Sector
Health
52-Week High
$16.14$759.55
52-Week Low
$5.48$621.75
Enterprise Value
$627.78M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.

The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.

S&P500 ETF

SPY trades at $749.08, down 0.77% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF approaches key resistance at $750 with support at $747. Recent news highlights analyst optimism with several firms projecting S&P 500 targets above 8,000 by year-end, though earnings season and inflation data remain key catalysts.

Outlook remains constructive given strong institutional sentiment and historical market performance, though risks include potential Fed policy shifts and valuation concerns. The dividend payment scheduled for July 31, 2026 provides income support, while technical consolidation near all-time highs suggests potential for breakout momentum if earnings deliver.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY